Wednesday, January 11, 2017 1:18:52 AM
SILVER SPRINGS, NV / ACCESSWIRE / January 3, 2017 / Kasten, Inc. (OTC PINK: KAST) announced today it has signed a Joint Venture agreement with Thru Pharma LLC dba DAKOTA Life Sciences for the purpose of promoting the development and marketing of Site Specific Penetration Technology (SSPT™ ) biopharmaceutical products.
Dakota Life Sciences is engaged in developing innovative health products utilizing SSPT™ technologies. These products include but are not limited to Thin Nail® (OTC First Aid Nail Antifungal), Symphony OTC First Aid Antibiotic, ThinNail® RX Topical Antifungal, Symphony ™ RX Topical Antibiotic, Reserve ™ Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as genomics-based companion diagnostics.
Under the terms of the Joint Venture Agreement, both parties will have equal ownership rights. “This new joint venture is uniquely positioned to optimize the development of DAKOTA’s biopharmaceutical product line. Together we will launch their portfolio of products to the market place. This JV further compliments our roll-up strategy of developing and commercializing innovative medical solutions,” stated Jose Delgado, CEO of Kasten, Inc.
DAKOTA Life Sciences is a leading anti-infectives private pharmaceutical Company with award-winning products designed to provide the highest efficacy for global patients at high risk of suffering from dangerous microbial and fungal infections.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
ReleaseID: 452045
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM